Yahoo
NasdaqCM - Delayed Quote USD

Bionano Genomics, Inc. (BNGO)

1.1800 +0.0200 (+1.72%)
At close: May 1 at 4:00:00 PM EDT
1.2100 +0.0300 (+2.54%)
After hours: May 1 at 7:42:42 PM EDT
Chart Range Bar
Loading chart for BNGO
  • Previous Close 1.1600
  • Open 1.1700
  • Bid 1.1500 x 100
  • Ask 1.2400 x 100
  • Day's Range 1.1600 - 1.2100
  • 52 Week Range 1.0600 - 5.5000
  • Volume 92,469
  • Avg. Volume 305,324
  • Market Cap (intraday) 13.089M
  • Beta (5Y Monthly) 1.60
  • PE Ratio (TTM) --
  • EPS (TTM) -4.8500
  • Earnings Date May 13, 2026
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 5.00

Bionano Genomics, Inc., together with its subsidiaries, provides genome analysis solutions in the Americas, Europe, the Middle East, Africa, China, Japan, South Korea, Singapore, India, and Australia. The company offers genome analysis software that enables genomics labs to analyze and interpret data across a range of platforms to generate informative data visualizations for streamlined and simple reporting of causal variants. It also provides Saphyr and Stratys systems, which are sample-to-result solutions for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr and Stratys instruments, which are single-molecule imagers; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight DNA; and Ionic purification system, which isolates and purifies nucleic acid molecules. In addition, the company offers Saphyr, Stratys, and Bionano compute servers; and VIA software, which offers one solution for solutions for cytogenetics and molecular genetics. Further, it provides testing and laboratory services comprising FirstStepDx PLUS, a chromosomal microarray for identifying an underlying genetic cause in individuals with autism spectrum disorder, developmental delay, and intellectual disability; Fragile X syndrome (FXS) testing services; NextStepDx PLUS, a exome sequencing test to identify genetic variants that are associated with disorders of childhood development; OGM-Dx HemeOne testing; OGM-Dx FSHD, a test for individuals suspected of having FSHD type 1; and OGM-Dx Postnatal Whole Genome SV and OGM-Dx Prenatal Whole Genome SV for comprehensive testing. Bionano Genomics, Inc. was founded in 2003 and is headquartered in San Diego, California.

bionano.com

95

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Recent News: BNGO

View More

Performance Overview: BNGO

Trailing total returns as of 5/1/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

BNGO
22.88%
S&P 500 (^GSPC)
5.62%

1-Year Return

BNGO
70.50%
S&P 500 (^GSPC)
29.01%

3-Year Return

BNGO
99.71%
S&P 500 (^GSPC)
73.47%

5-Year Return

BNGO
99.97%
S&P 500 (^GSPC)
72.92%

Earnings Trends: BNGO

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q4 FY25
Revenue 7.95M
Earnings -7.93M

Q1

FY25

Q2

FY25

Q3

FY25

Q4

FY25

-5M
0
5M

Analyst Insights: BNGO

View More

Analyst Price Targets

4.00
5.00 Average
1.1800 Current
6.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 4/13/2026
Analyst HC Wainwright & Co.
Rating Action Maintains
Rating Buy
Price Action Lowers
Price Target 7 -> 6

Statistics: BNGO

View More

Valuation Measures

Annual
As of 5/1/2026
  • Market Cap

    13.09M

  • Enterprise Value

    734.56k

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    0.23

  • Price/Book (mrq)

    0.29

  • Enterprise Value/Revenue

    0.03

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -92.59%

  • Return on Assets (ttm)

    -27.74%

  • Return on Equity (ttm)

    -66.15%

  • Revenue (ttm)

    28.51M

  • Net Income Avi to Common (ttm)

    -26.39M

  • Diluted EPS (ttm)

    -4.8500

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    19.27M

  • Total Debt/Equity (mrq)

    38.03%

  • Levered Free Cash Flow (ttm)

    -4.58M

Compare To: BNGO

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Company Insights: BNGO

Fair Value

1.1800 Current

Dividend Score

0 Low
Sector Avg.
100 High

Hiring Score

0 Low
Sector Avg.
100 High

Insider Sentiment Score

0 Low
Sector Avg.
100 High

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: